Funder
National Natural Science Foundation of China
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference37 articles.
1. Cancer statistics, 2022. CA;Siegel;A Cancer Journal for Clinicians,2022
2. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung;Isomoto;Cancer,2020
3. Third generation EGFR TKIs: current data and future directions;Tan;Mol. Cancer,2018
4. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer;Wang;J. Hematol. Oncol.,2019
5. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC;Linardou;Nat. Rev. Clin. Oncol.,2009